Geode Capital Management
LPCN icon

Geode Capital Management’s Lipocine LPCN Stock Holding History

Geode Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Buy
63,135
+685
+1% +$5.97K ﹤0.01% 3583
2025
Q4 		$502K Buy
62,450
+1,374
+2% +$4.62K ﹤0.01% 3582
2025
Q3 		$175K Hold
61,076
– – ﹤0.01% 3968
2025
Q2 		$193K Buy
61,076
+2,242
+4% +$7.28K ﹤0.01% 3886
2025
Q1 		$187K Buy
58,834
+1,370
+2% +$5.3K ﹤0.01% 3872
2024
Q4 		$280K Buy
57,464
+3,248
+6% +$16.5K ﹤0.01% 3790
2024
Q3 		$243K Buy
54,216
+1,037
+2% +$5.21K ﹤0.01% 3845
2024
Q2 		$438K Buy
53,179
+4,325
+9% +$27K ﹤0.01% 3611
2024
Q1 		$254K Hold
48,854
– – ﹤0.01% 3859
2023
Q4 		$135K Hold
48,854
– – ﹤0.01% 4082
2023
Q3 		$144K Buy
48,854
+24
+0% +$101 ﹤0.01% 4116
2023
Q2 		$244K Buy
48,830
+3
+0% +$14 ﹤0.01% 3953
2023
Q1 		$264K Hold
48,827
– – ﹤0.01% 3915
2022
Q4 		$318K Sell
48,827
-119
-0.2% -$867 ﹤0.01% 3859
2022
Q3 		$374K Hold
48,946
– – ﹤0.01% 3883
2022
Q2 		$666K Buy
48,946
+531
+1% +$8.28K ﹤0.01% 3607
2022
Q1 		$1.13M Sell
48,415
-81
-0.2% -$1.7K ﹤0.01% 3562
2021
Q4 		$817K Hold
48,496
– – ﹤0.01% 3803
2021
Q3 		$898K Buy
48,496
+3,756
+8% +$82.9K ﹤0.01% 3735
2021
Q2 		$1.06M Buy
44,740
+9,227
+26% +$217K ﹤0.01% 3561
2021
Q1 		$911K Buy
35,513
+8,996
+34% +$260K ﹤0.01% 3595
2020
Q4 		$613K Buy
26,517
+8,837
+50% +$213K ﹤0.01% 3532
2020
Q3 		$423K Buy
17,680
+5,928
+50% +$157K ﹤0.01% 3475
2020
Q2 		$251K Hold
11,752
– – ﹤0.01% 3598
2020
Q1 		$95K Hold
11,752
– – ﹤0.01% 3781
2019
Q4 		$76K Buy
11,752
+202
+2% +$5.17K ﹤0.01% 4020
2019
Q3 		$551K Hold
11,550
– – ﹤0.01% 3443
2019
Q2 		$382K Buy
11,550
+1,123
+11% +$34.7K ﹤0.01% 3563
2019
Q1 		$409K Buy
10,427
+4,284
+70% +$131K ﹤0.01% 3507
2018
Q4 		$135K Hold
6,143
– – ﹤0.01% 3792
2018
Q3 		$144K Hold
6,143
– – ﹤0.01% 3849
2018
Q2 		$135K Hold
6,143
– – ﹤0.01% 3815
2018
Q1 		$159K Hold
6,143
– – ﹤0.01% 3745
2017
Q4 		$359K Hold
6,143
– – ﹤0.01% 3482
2017
Q3 		$414K Hold
6,143
– – ﹤0.01% 3429
2017
Q2 		$419K Sell
6,143
-875
-12% -$57.1K ﹤0.01% 3415
2017
Q1 		$465K Buy
7,018
+367
+6% +$23.8K ﹤0.01% 3332
2016
Q4 		$416K Buy
6,651
+206
+3% +$13K ﹤0.01% 3337
2016
Q3 		$488K Buy
6,445
+261
+4% +$16.2K ﹤0.01% 3259
2016
Q2 		$319K Buy
6,184
+951
+18% +$147K ﹤0.01% 3408
2016
Q1 		$903 Sell
5,233
-3
-0.1% -$512 ﹤0.01% 2931
2015
Q4 		$1.15M Buy
5,236
+6
+0.1% +$1.26K ﹤0.01% 2832
2015
Q3 		$1.05M Buy
5,230
+221
+4% +$51.1K ﹤0.01% 2842
2015
Q2 		$730K Buy
5,009
+1,663
+50% +$206K ﹤0.01% 3046
2015
Q1 		$392K Buy
3,346
+537
+19% +$58.4K ﹤0.01% 3294
2014
Q4 		$251K Hold
2,809
– – ﹤0.01% 3496
2014
Q3 		$291K Buy
+2,809
New +$349K ﹤0.01% 3415

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Geode Capital Management's LPCN Position: Q1 2026 in Review

Geode Capital Management increased its Lipocine (LPCN) stake by 1.1% in Q1 2026, buying an estimated $5.97K and bringing the position to 63,135 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #3583.

Geode Capital Management first reported a position in LPCN in Q3 2014 and has held it in 47 quarters since. The position peaked at $1.15M in Q4 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Geode Capital Management held 63,135 shares of Lipocine worth $505K as of Q1 2026.
  • Geode Capital Management bought 685 Lipocine shares in Q1 2026, an estimated $5.97K.
  • Lipocine made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3583 holding.
  • Geode Capital Management first reported a position in Lipocine in Q3 2014 and has held it in 47 quarters since.
  • Geode Capital Management's Lipocine position peaked at $1.15M in Q4 2015.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.